Christopher A Maher

Washington University in St. Louis
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Supplementary Figure S11. Cell-free DNA methylation levels of the top 10 least stem-like signature genes in plasma. The box and whisker plots summarize the promoter methylation rates for the top 10 least stem-like genes in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients. p values were calculated by the Student’s t test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.

Year:

2025

Supplementary Figure S7. Distribution of differentially methylated regions in mCRPC plasma cell-free DNA. (A) Distribution of hypomethylated and hypermethylated genic DMRs in pre-treatment plasma cfDNA in AR /enhancer altered lethal mCRPC (compared to AR /enhancer wild-type mCRPC). (B) Genomic annotation of genic DMRs based on their location in the genome. (C) Top 50 hypermethylated DMRs found in pre-treatment plasma cfDNA from AR /enhancer altered lethal mCRPC patients (compared to AR /enhancer wild-type mCRPC). cfDNA, cell-free DNA; CDS, coding sequence; DMRs, differentially methylated regions; mCRPC, metastatic castration-resistant prostate cancer; UTR, untranslated region.

Year:

2025

Supplementary Figure S2. Kaplan-Meier analysis based on plasma collected prior to first-line androgen receptor-signaling inhibitor (ARSI) treatment according to (A,B) Androgen receptor ( AR ) gene body status and (C,D) AR enhancer region status in 63 patients with metastatic castration-resistant prostate cancer (mCRPC). p values were calculated by the log-rank test and hazard ratios (HRs) by the Mantel-Haenszel method.

Year:

2025

Supplementary Figure S10. Cell-free DNA methylation levels of the top 10 most stem-like signature genes in plasma. The box and whisker plots summarize promoter methylation rates for the top 10 most stem-like signature genes in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients. p values were calculated by the Student’s t test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.

Year:

2025

Supplementary Figure S1. Genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) samples profiled using EnhanceAR-Seq. EnhanceAR-Seq, Enhancer and neighboring loci of Androgen Receptor Sequencing.

Year:

2025

Supplementary Figure S4. Summary of alterations in biologically relevant pathways found in pre-ARSI plasma cell-free DNA of 63 metastatic castration-resistant prostate cancer patients. ARSI, androgen receptor-signaling inhibitors.

Year:

2025

Supplementary Figure S9. Cell-free DNA methylation analysis of differentially accessible transcription factor binding sites. The box and whisker plots summarize methylation levels in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients after z-score transformation of the 10,000 TF binding sites corresponding to each of the top 20 TFs that are (A) most accessible and (B) least accessible in cfDNA from AR /enhancer altered lethal high-risk mCRPC patients. p values were calculated by the Mann-Whitney U test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.

Year:

2025

Supplementary Figure S6. Kaplan–Meier survival analysis of the 43-patient mCRPC cohort that also underwent genome-wide EM-seq, according to (A,B) AR /enhancer alteration status and (C,D) median-split ichorCNA-based median tumor fraction. p values were calculated by the log-rank test and hazard ratios (HRs) by the Mantel-Haenszel method. cfDNA, cell-free DNA; mCRPC; metastatic castration-resistant prostate cancer.

Year:

2025

Supplementary Figure S8. Transcription factor analysis in localized prostate cancer versus blood. Log2 fold change of the 20 TFs with most accessible and least accessible binding sites in plasma cell-free DNA (see Fig. 4E, Table S12 and Table S13) in localized prostate adenocarcinoma tumors from TCGA (n = 496) versus blood samples from GTEX (n = 337) (Methods). p value was calculated by Student’s t test. GTEX, Genotype-Tissue Expression project; TCGA, The Cancer Atlas Genome Atlas project; TF, transcription factor.

Year:

2025

Supplementary Figure S5. Kaplan-Meier survival analysis based on plasma collected prior to first-line androgen receptor-signaling inhibitor (ARSI) treatment in 63 mCRPC patients according to (A,B) PTEN copy number loss status in cfDNA, (C,D) PTEN copy number loss or mutation in cfDNA, and (E,F) alteration in AR /Enhancer or PTEN in cfDNA. p values were calculated by the log-rank test and hazard ratios (HRs) by the Mantel-Haenszel method. cfDNA, cell-free DNA; mCRPC; metastatic castration-resistant prostate cancer.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Collaborators (12)

Meng Zhang

Assistant Professor of Urology

Emory University

UNITED STATES
View details

Oliver Sartor

Tulane University School of Medicine

UNITED STATES
View details

David A. Quigley

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Sean Park

Professor

Mayo Clinic Rochester

UNITED STATES
View details

Jace Webster

Full Specialist

University of California, San Francisco

UNITED STATES
View details

Peter Harris

Staff Scientist

Washington University in St. Louis

UNITED STATES
View details

Aadel A. Chaudhuri

Washington University School of Medicine

UNITED STATES
View details

Jacob Orme

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Pradeep Chauhan

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Felix Y. Feng

University of California

UNITED STATES
View details

Fabrice Lucien

Assistant Professor

Mayo Clinic Minnesota

UNITED STATES
View details

Russell K. Pachynski

Washington University School of Medicine

UNITED STATES
View details